How India Exports Atenolol to the World

Atenolol, a beta-blocker used primarily for treating hypertension and angina, has been available in the United States since its initial approval. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for atenolol, indicating a well-established generic market. Notably, Martec Pharmaceuticals, Inc. received approval for ANDA 74-404 on May 14, 1998, for atenolol and chlorthalidone tablets.

As of March 2026, there are no active FDA import alerts specifically targeting atenolol products from India. However, Import Alert 66-66, issued on October 22, 2024, addresses concerns about active pharmaceutical ingredients (APIs) that may be misbranded due to labeling deficiencies. While this alert does not explicitly mention atenolol, it underscores the importance of compliance with FDA labeling requirements for all APIs imported into the U.S.

India's significant role in supplying atenolol to the U.S. market is evident, with 300 active Indian exporters contributing to 39.1% of India's atenolol exports destined for the United States. This substantial market share highlights the critical need for these exporters to adhere strictly to FDA regulations to maintain uninterrupted market access.

In the European Union, atenolol is subject to national marketing authorizations, as it predates the centralized approval system managed by the European Medicines Agency (EMA). Periodic safety update reports (PSURs) are conducted to monitor the drug's safety profile. For instance, the EMA published the PSUSA/00000259/202502 assessment for atenolol on November 26, 2025, resulting in variations to product information to enhance patient safety. (ema.europa.eu)

The United Kingdom, following its departure from the EU, continues to regulate atenolol through the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA aligns with EU standards, ensuring that atenolol products meet stringent safety and efficacy requirements.

Compliance with Good Manufacturing Practice (GMP) standards is mandatory for all pharmaceutical products in the EU and UK. Indian exporters must ensure their manufacturing facilities are GMP-certified to maintain access to these markets.

Atenolol is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is crucial for ensuring product quality and facilitating international trade.

In India, atenolol is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including atenolol, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of atenolol formulations, ensuring compliance with national regulations.

Atenolol's primary patents have long expired, leading to a competitive generic market. This expiration has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets.

In November 2025, the EMA published the PSUSA/00000259/202502 assessment for atenolol, resulting in variations to product information to enhance patient safety. (ema.europa.eu)

In October 2024, the FDA issued Import Alert 66-66, addressing concerns about APIs that may be misbranded due to labeling deficiencies. While not specific to atenolol, this alert emphasizes the importance of compliance with FDA labeling requirements for all APIs imported into the U.S.

These developments highlight the dynamic nature of the regulatory landscape for atenolol and underscore the necessity for exporters to stay informed and compliant with evolving standards.

India's pharmaceutical industry, including the production of atenolol, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to vulnerabilities stemming from China's regulatory changes, environmental policies, and geopolitical tensions.

In recent years, environmental crackdowns in China have led to the shutdown of several chemical manufacturing units, causing disruptions in the supply of essential raw materials. For instance, in 2018, the closure of Chinese companies due to environmental non-compliance adversely affected Indian pharmaceutical manufacturers, leading to increased costs and supply chain uncertainties. Such events highlight the risks associated with over-reliance on a single country for critical raw materials.

The export market for atenolol from India is notably concentrated among a few key players. The top five exporters—IPCA Laboratories Limited, Unichem Laboratories Limited, Aurobindo Pharma Ltd, Zydus Lifesciences Limited, and J B Chemicals and Pharmaceuticals Limited—collectively account for 60.2% of the total export value. IPCA Laboratories Limited alone holds a 20.5% share, amounting to $8.3 million USD. This high level of supplier concentration poses a single-source risk, where disruptions affecting any of these major exporters could significantly impact the global supply of atenolol.

To mitigate such risks, the Indian government has introduced the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. While this initiative is a step towards enhancing self-reliance, its effectiveness in diversifying the supplier base and reducing concentration risks remains to be fully realized.

Recent geopolitical tensions have severely impacted global shipping routes critical to the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz following US-Israeli strikes on Iran led to a significant disruption in maritime traffic. This strait is a vital passage for approximately 20% of the world's oil and natural gas, and its closure has caused oil prices to surge and shipping routes to be rerouted, resulting in increased transit times and costs.

Additionally, the Red Sea has experienced heightened threats to commercial shipping, with attacks on vessels leading major shipping companies to suspend operations in the area. These disruptions have forced rerouting via the Cape of Good Hope, adding approximately 3,000-3,500 nautical miles and 10 to 14 days to transit times. Such delays and increased costs can adversely affect the timely delivery of pharmaceuticals, including atenolol, to global markets.

• Diversify API and KSM Sources: Reduce dependency on Chinese imports by developing alternative sources for APIs and KSMs, including domestic production and sourcing from other countries.

• Enhance Domestic Manufacturing: Leverage government initiatives like the PLI scheme to strengthen domestic API manufacturing capabilities, thereby reducing reliance on external suppliers.

• Strengthen Supplier Relationships: Establish strategic partnerships with multiple suppliers to mitigate risks associated with supplier concentration and ensure a more resilient supply chain.

• Monitor Geopolitical Developments: Implement robust monitoring systems to stay informed about geopolitical events that could impact shipping routes and supply chains, allowing for proactive adjustments.

• Develop Contingency Plans: Create comprehensive contingency plans that include alternative shipping routes and logistics strategies to address potential disruptions in key maritime passages.

RISK_LEVEL: HIGH